Although MEK inhibitors did not demonstrate apparent effectiveness for AML, pan-RAF inhibitors, especially in combination with BCL-2 inhibitors, represent a promising strategy in AML therapy. This evidence concerns the gene MAP2K7 and acute myeloid leukemia.